Cor Vasa 2020, 62(4):419-422 | DOI: 10.33678/cor.2020.061

(Doping, dietary supplements, and cardiovascular system)

Libor Vítek
IV. interní klinika a Ústav lékařské biochemie a laboratorní diagnostiky, 1. lékařská fakulta Univerzity Karlovy a Všeobecná fakultní nemocnice v Praze

Dietary supplements and various other supporting preparations are widely used in elite as well as hobby sport. However, their use might be associated with serious health risks involving cardiovascular impairment. These include direct damage of vessels and myocardium by substances prohibited because of their health impairing effects, but also by these substances contaminating allowed sports supplements, by mutual amplification of bioactive effects of multiple substances used often by athletes, or by biologically active, potentially cardiotoxic substances present in natural products. The spectrum of harmful cardiovascular effects is wide, from relatively less serious to fatal consequences. Because of these reasons, it is important to analyse cardiovascular problems of athletes cautiously, and take seriously into account potentially cardiotoxic effects of sports supplements used by athletes.

Keywords: Adverse effects, Cardiovascular toxicity, Dietary supplements, Doping, Sports

Received: June 5, 2020; Revised: June 10, 2020; Accepted: June 10, 2020; Published: September 16, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítek L. (Doping, dietary supplements, and cardiovascular system). Cor Vasa. 2020;62(4):419-422. doi: 10.33678/cor.2020.061.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lun V, Erdman KA, Fung TS, Reimer RA. Dietary supplementation practices in Canadian high-performance athletes. Int J Sport Nutr Exerc Metab 2012;22:31-37. Go to original source... Go to PubMed...
    2. Bailey RL, Gahche JJ, Lentino CV, et al. Dietary supplement use in the United States, 2003-2006. J Nutr 2011;141:261-266. Go to original source... Go to PubMed...
    3. Pipe A, Ayotte C. Nutritional supplements and doping. Clin J Sport Med 2002;12:245-249. Go to original source... Go to PubMed...
    4. Maughan RJ. Contamination of dietary supplements and positive drug tests in sport. J Sports Sci 2005;23:883-889. Go to original source... Go to PubMed...
    5. Geyer H, Parr MK, Koehler K, et al. Nutritional supplements cross-contaminated and faked with doping substances. J Mass Spectrom 2008;43:892-902. Go to original source... Go to PubMed...
    6. Maughan RJ. Quality assurance issues in the use of dietary supplements, with special reference to protein supplements. J Nutr 2013;143:1843S-1847S. Go to original source... Go to PubMed...
    7. Mathews NM. Prohibited contaminants in dietary supplements. Sports Health 2018;10:19-30. Go to original source... Go to PubMed...
    8. Tucker J, Fischer T, Upjohn L, et al. Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. JAMA Netw Open 2018;1:e183337. Go to original source... Go to PubMed...
    9. Geller AI, Shehab N, Weidle NJ, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med 2015;373:1531-1540. Go to original source... Go to PubMed...
    10. Bowers LD. Abuse of performance-enhancing drugs in sport. Ther Drug Monit 2002;24:178-181. Go to original source... Go to PubMed...
    11. Dhar R, Stout CW, Link MS, et al. Cardiovascular toxicities of performance-enhancing substances in sports. Mayo Clin Proc 2005;80:1307-1315. Go to original source... Go to PubMed...
    12. Kersey RD, Elliot DL, Goldberg L, et al. National Athletic Trainers' Association position statement: anabolic-androgenic steroids. J Athl Train 2012;47:567-588. Go to original source... Go to PubMed...
    13. Pope HG, Jr., Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 2014;35:341-375. Go to original source... Go to PubMed...
    14. Hernandez-Guerra AI, Tapia J, Menendez-Quintanal LM, Lucena JS. Sudden cardiac death in anabolic androgenic steroids abuse: case report and literature review. Forensic Sci Res 2019;4:267-273. Go to original source... Go to PubMed...
    15. Parssinen M, Kujala U, Vartiainen E, et al. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 2000;21:225-227. Go to original source... Go to PubMed...
    16. Deligiannis A, Bjornstad H, Carre F, et al. ESC study group of sports cardiology position paper on adverse cardiovascular effects of doping in athletes. Eur J Cardiovasc Prev Rehabil 2006;13:687-694. Go to original source... Go to PubMed...
    17. Liu JD, Wu YQ. Anabolic-androgenic steroids and cardiovascular risk. Chin Med J (Engl) 2019;132:2229-2236. Go to original source... Go to PubMed...
    18. Zahn KA, Li RL, Purssell RA. Cardiovascular toxicity after ingestion of "herbal ecstacy". J Emerg Med 1999;17:289-291. Go to original source... Go to PubMed...
    19. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clin Proc 2002;77:12-16. Go to original source... Go to PubMed...
    20. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 2000;343:1833-1838. Go to original source... Go to PubMed...
    21. Food Drug Administration HHS. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule. Fed Regist 2004;69:6787-6854. Go to PubMed...
    22. Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA 1991;265:1152-1154. Go to original source... Go to PubMed...
    23. Bachs L, Morland H. Acute cardiovascular fatalities following cannabis use. Forensic Sci Int 2001;124:200-203. Go to original source... Go to PubMed...
    24. Kloner RA, Hale S, Alker K, Rezkalla S. The effects of acute and chronic cocaine use on the heart. Circulation 1992;85:407-419. Go to original source... Go to PubMed...
    25. Prather ID, Brown DE, North P, Wilson JR. Clenbuterol: a substitute for anabolic steroids? Med Sci Sports Exerc 1995;27:1118-1121. Go to original source...
    26. Pluim BM, de Hon O, Staal JB, et al. β2-agonists and physical performance: a systematic review and meta-analysis of randomized controlled trials. Sports Med 2011;41:39-57. Go to original source... Go to PubMed...
    27. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta- -analysis. Chest 2004;125:2309-2321. Go to original source... Go to PubMed...
    28. Chodorowski Z, Sein Anand J. Acute poisoning with clenbuterol - a case report. Przegl Lek 1997;54:763-764. Go to PubMed...
    29. Kierzkowska B, Stanczyk J, Kasprzak JD. Myocardial infarction in a 17-year-old body builder using clenbuterol. Circ J 2005;69:1144-1146. Go to original source... Go to PubMed...
    30. Milano G, Chiappini S, Mattioli F, et al. β2 Agonists as misusing drugs? Assessment of both clenbuterol- and salbutamol--related European Medicines Agency pharmacovigilance database reports. Basic Clin Pharmacol Toxicol 2018;123:182-187. Go to original source... Go to PubMed...
    31. Grimmer NM, Gimbar RP, Bursua A, Patel M. Rhabdomyolysis secondary to clenbuterol use and exercise. J Emerg Med 2016;50:e71-e74. Go to original source... Go to PubMed...
    32. Jelkmann W. Erythropoietin doping: Cardiovascular effects in athletes. Ann Sports Med Res 2020;7:1142.
    33. Piloto N, Teixeira HM, Teixeira-Lemos E, et al. Erythropoietin promotes deleterious cardiovascular effects and mortality risk in a rat model of chronic sports doping. Cardiovasc Toxicol 2009;9:201-210. Go to original source... Go to PubMed...
    34. Gareau R, Audran M, Baynes RD, et al. Erythropoietin abuse in athletes. Nature 1996;380:113. Go to original source... Go to PubMed...
    35. Meyers DE, Cuneo RC. Controversies regarding the effects of growth hormone on the heart. Mayo Clin Proc 2003;78:1521-1526. Go to original source... Go to PubMed...
    36. Cadwallader AB, de la Torre X, Tieri A, Botre F. The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: pharmacology, toxicology and analysis. Br J Pharmacol 2010;161:1-16. Go to original source... Go to PubMed...
    37. Chung MK. Vitamins, supplements, herbal medicines, and arrhythmias. Cardiol Rev 2004;12:73-84. Go to original source... Go to PubMed...
    38. Navarro VJ, Khan I, Bjornsson E, et al. Liver injury from herbal and dietary supplements. Hepatology 2017;65:363-373. Go to original source... Go to PubMed...
    39. Pollak PT. Herbal cardiotoxicity: Can mother Nature hurt the heart? Can J Cardiol 2016;32:291-293. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes